<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04460066</url>
  </required_header>
  <id_info>
    <org_study_id>ZKAB001-LEES-2020-02</org_study_id>
    <nct_id>NCT04460066</nct_id>
  </id_info>
  <brief_title>A Study of Anti-PD-L1 Antibody in Perioperative Chemotherapy of Esophageal Carcinoma.</brief_title>
  <official_title>A Randomized, Double-blind, Placebo-controlled Phase Ib/II Clinical Study of Anti-pd-l1 Monoclonal Antibody Injection (ZKAB001) in Perioperative Treatment of Esophageal Squamous Cell Carcinoma.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lee's Pharmaceutical Limited</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Lee's Pharmaceutical Limited</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a randomized, double-blind, placebo-controlled Ib/Ⅱ clinical study to evaluate the
      safety and effect of anti-PD-L1 antibody (ZKAB001) in perioperative chemotherapy of
      esophageal squamous carcinoma in combination with Alb-paclitaxel and cisplatin. The
      immunotherapy will be given before and after the operation every three weeks.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 1, 2020</start_date>
  <completion_date type="Anticipated">September 1, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 1, 2022</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>major pathologic response rate</measure>
    <time_frame>One week after surgery.</time_frame>
    <description>The rate of pathologic 1a and 1b after neoadjuvant chemotherapy.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression free survival</measure>
    <time_frame>From date of randomization until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.</time_frame>
    <description>The 2-year progression free survival of the whole group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>disease free survival</measure>
    <time_frame>From date of surgery until the date of death from any cause or the date of first documented disease progression whichever came first, assessed up to 24 months.</time_frame>
    <description>The 2-year disease free survival of the whole group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>From date of randomization until the date of death from any cause or the date of last follow-up whichever came first, assessed up to 24 months.</time_frame>
    <description>The 2-year overall survival of the whole group.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>R0 resection rate</measure>
    <time_frame>One week after surgery.</time_frame>
    <description>The R0 resection rate of esophagectomy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>treatment-related adverse events rate</measure>
    <time_frame>From the enrollment to 90 days later of the last chemotherapy.</time_frame>
    <description>The incidence rate of treatment-related adverse events of the whole group assessed by CTCAE v5.0.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Esophageal Cancer</condition>
  <arm_group>
    <arm_group_label>PD-L1 group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>All patients will receive 16 cycles of anti-PD-L1 antibody (5mg/kg, IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>placebo group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>All patients will receive 6 cycles of placebo ( IV, every 3 weeks) , concurrently with 6 cycles of albumin-bound paclitaxel and cisplatin (albumin-bound paclitaxel 125mg/m2 on days 1, 8 and cisplatin 75 mg/m2 on day 1 every 3 weeks).</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>anti-PD-L1 antibody</intervention_name>
    <description>Patients will receive 16 cycles of anti-PD-L1 antibody 5mg/kg IV on day 1 every 3 weeks.</description>
    <arm_group_label>PD-L1 group</arm_group_label>
    <other_name>ZKAB001</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>albumin bound paclitaxel</intervention_name>
    <description>Patients will receive 6 cycles of albumin bound paclitaxel 125mg/m2 on days 1, 8 every 3 weeks .</description>
    <arm_group_label>PD-L1 group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
    <other_name>ABRAXANE</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cisplatin</intervention_name>
    <description>Patients will receive 6 cycles of cisplatin 75mg/m2 on day 1 every 3 weeks.</description>
    <arm_group_label>PD-L1 group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>Patients will receive 6 cycles of placebo IV on day 1 every 3 weeks.</description>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical resection of esophageal carcinoma</intervention_name>
    <description>Patients will receive radical resection of esophageal carcinoma after 4 cycles of chemotherapy.</description>
    <arm_group_label>PD-L1 group</arm_group_label>
    <arm_group_label>placebo group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Key inclusion Criteria:

          1. Aged 18 to 70 years old of either gender;

          2. A histopathological diagnosis of esophageal squamous cell carcinoma with a clinical
             stage of T2N+M0 or T3-4aN+/-M0 according to the 8th edition of the UICC staging
             system;

          3. ECOG score 0-1;

          4. Estimated life expectancy &gt;3 months;

          5. BMI ≥18.5kg/m2 or PG-SGA score A/B;

          6. The function of important organs meets the following requirements:

               1. white blood cell count (WBC) ≥ 4.0×109/L, absolute neutrophil count (ANC) ≥
                  1.5×109/L, platelets ≥ 100×109/L, hemoglobin ≥ 90g/L;

               2. ALT, AST and AKP ≤ 2.5×ULN;

               3. serum albumin ≥ 30g/L;

               4. total bilirubin ≤ 1.5×ULN;

               5. serum creatinine ≤ 1.0×ULN, creatinine clearance rate ≥80 mL/min;

               6. INR ≤ 1.5, PT≤ 1.5×ULN;

          7. Cardiac function: I, pulmonary function: VC%&gt;60%, FEV1 &gt;1.2L, FEV1% &gt;40%, DLCO &gt;40%,
             liver function: Child-Pugh 5-6;

          8. Serum HCG negative in premenopausal women ;

          9. Ability to understand the study and sign informed consent.

        Key exclusion Criteria:

          1. Cervical esophageal carcinoma;

          2. Patients who have been treated previously with anti-tumor therapy (including
             chemotherapy, radiotherapy, surgery, immunotherapy, etc.);

          3. Known or suspected allergy or hypersensitivity to monoclonal antibodies, any
             ingredients of anti-PD-L1 antibody and chemotherapeutic drugs;

          4. Active autoimmune diseases;

          5. A history of allogeneic stem cell transplantation and organ transplantation;

          6. A history of interstitial lung disease or non-infectious pneumonia;

          7. Patients who cannot tolerate chemotherapy or surgery due to severe cardiac, lung,
             liver or kidney dysfunction, or hematopoietic disease or cachexia;

          8. A history of immunodeficiency (including a positive HIV test result), or other
             acquired or congenital immunodeficiency diseases;

          9. Presence of active hepatitis B (HBV DNA ≥ 200 IU/mL or 103 copies/mL), hepatitis C
             (positive for hepatitis C antibody, and HCV-RNA levels higher than the lower limit of
             the assay);

         10. A history of active pulmonary tuberculosis infection within 1 year or a history of
             active pulmonary tuberculosis infection more than 1 year ago but without formal
             anti-tuberculosis treatment;

         11. A history of malignancies other than esophageal cancer before enrollment, excluding
             non-melanoma skin cancer, in situ cervical cancer, or cured early prostate cancer.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>SHUGENG GAO, MD</last_name>
    <role>Study Director</role>
    <affiliation>Chinese Academy of Medical Sciences and Peking Union Medical College</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>SHUGENG GAO, MD</last_name>
    <phone>86-010-87788530</phone>
    <email>gaoshugeng@vip.sina.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>YONG LI, MD</last_name>
    <phone>86-010-87788530</phone>
    <email>liyongdoctor@126.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chinese Academy of Medical Sciences and Peking Union Medical College</name>
      <address>
        <city>Beijing</city>
        <state>Beijing</state>
        <zip>100000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <link>
    <url>http://gco.iarc.fr/today/data/factsheets/cancers/6Oesophagus-fact-sheet.pdf.</url>
    <description>GLOBOCAN 2018: oesophagus cancer fact sheet</description>
  </link>
  <reference>
    <citation>Kelsen DP, Ginsberg R, Pajak TF, Sheahan DG, Gunderson L, Mortimer J, Estes N, Haller DG, Ajani J, Kocha W, Minsky BD, Roth JA. Chemotherapy followed by surgery compared with surgery alone for localized esophageal cancer. N Engl J Med. 1998 Dec 31;339(27):1979-84.</citation>
    <PMID>9869669</PMID>
  </reference>
  <reference>
    <citation>Lin CC, Hsu CH, Cheng JC, Wang HP, Lee JM, Yeh KH, Yang CH, Lin JT, Cheng AL, Lee YC. Concurrent chemoradiotherapy with twice weekly paclitaxel and cisplatin followed by esophagectomy for locally advanced esophageal cancer. Ann Oncol. 2007 Jan;18(1):93-98. doi: 10.1093/annonc/mdl339. Epub 2006 Oct 6.</citation>
    <PMID>17028244</PMID>
  </reference>
  <reference>
    <citation>Polee MB, Tilanus HW, Eskens FA, Hoekstra R, Van der Burg ME, Siersema PD, Stoter G, Van der Gaast A. Phase II study of neo-adjuvant chemotherapy with paclitaxel and cisplatin given every 2 weeks for patients with a resectable squamous cell carcinoma of the esophagus. Ann Oncol. 2003 Aug;14(8):1253-7.</citation>
    <PMID>12881388</PMID>
  </reference>
  <reference>
    <citation>Shapiro J, van Hagen P, Lingsma HF, Wijnhoven BP, Biermann K, ten Kate FJ, Steyerberg EW, van der Gaast A, van Lanschot JJ; CROSS Study Group. Prolonged time to surgery after neoadjuvant chemoradiotherapy increases histopathological response without affecting survival in patients with esophageal or junctional cancer. Ann Surg. 2014 Nov;260(5):807-13; discussion 813-4. doi: 10.1097/SLA.0000000000000966.</citation>
    <PMID>25379852</PMID>
  </reference>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 1, 2020</study_first_submitted>
  <study_first_submitted_qc>July 5, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 7, 2020</study_first_posted>
  <last_update_submitted>July 6, 2020</last_update_submitted>
  <last_update_submitted_qc>July 6, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 8, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>esophageal cancer</keyword>
  <keyword>immunotherapy</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esophageal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
    <mesh_term>Antibodies</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

